← All trials
NCT04678648
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 16, 2021
- Primary completion
- Jan 16, 2024
- Completion date
- Mar 5, 2024
- First posted
- Dec 22, 2020
- Last posted
- Sep 1, 2021
- Enrollment
- 134
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RasCal Therapeutics, Inc.Lead sponsor
- RasCal Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.